enGene USA, Inc.Transition and Modification Agreement • July 24th, 2024 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
On or about February 13, 2024, you and the Company entered into a Transition and Modification Agreement (the “Agreement”). For good and valuable consideration, you and the Company have agreed to amend the Agreement as set forth in this letter agreement (the “Amendment”). Capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to them in the Agreement.
